Home » Utilizing Same-Day Sepsis Pathogen ID for Faster Therapy, Enhanced Stewardship, Improved Outcomes
Utilizing Same-Day Sepsis Pathogen ID for Faster Therapy, Enhanced Stewardship, Improved Outcomes
Cornelius J. Clancy, MD - Associate Professor of Medicine, Infectious Diseases Division and Director, Mycology Program, University of Pittsburgh
Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes and cost. One of the major hurdles to effective sepsis management is the limitations of conventional diagnostics, which are blood-culture-based and take 1 to 5 or more days to identify sepsis-causing pathogens. Blood culture also misses 35-50% of infections altogether on the first blood draw and can be greatly affected by the presence of antimicrobials. These delays impact patient outcomes as one hour of delayed treatment increases mortality risk by nearly 8%.
To advance sepsis care, hospitals are turning to new technology that does not rely on blood culture. This year, six new peer-reviewed studies have been published on T2Direct Diagnostics, which provide blood culture-independent sepsis pathogen ID results in 3 to 5 hours. Due to improved detection, these studies from the U.S. and EU demonstrate that clinicians can achieve faster-targeted therapy, better outcomes, enhanced stewardship, and reduced cost of care. The T2Dx Instrument runs the first FDA-cleared tests to identify deadly sepsis-causing pathogens in whole blood: the T2Candida Panel and the now FDA-Cleared T2Bacteria Panel.
In this webinar you will:
Review the latest clinical data on the accuracy and impact of blood culture-independent diagnostics
Demonstrate the potential for new diagnostics to improve outcomes for patients suspected of sepsis while improving stewardship
Understand opportunities and barriers to implementation of blood culture-independent diagnostics into routine clinical care and sepsis management protocols
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.